A new in vivo pharmacokinetic recall study involving 114 participants in the Estonian Biobank has provided the first clinical confirmation that previously uncharacterized genetic variants in the drug-metabolizing enzymes CYP2C19 and CYP2D6 significantly affect how drugs are processed in the human body. These results emphasize the need to look beyond common pharmacogenetic markers to improve the precision of personalized drug therapy. The paper is published in the journal npj Genomic Medicine.
This article was originally published on MedicalXpress.com
